Evolocumab (REPATHA) is a monoclonal antibody targeting PCSK9, leading to increased recycling of LDL receptors and significant reductions in LDL cholesterol levels.
Its use in patients already on statins offers incremental LDL-C lowering, making it particularly useful in high-risk populations like T1D, where residual cardiovascular risk remains high despite standard therapy.
At the American Diabetes Association (ADA) annual conference held in Chicago, emerging data spotlighted the elevated cardiovascular risk faced by individuals with T1D. Amgen presented an abstract titled “Cardiovascular Efficacy of Evolocumab in Persons with T1D: Insights from the FOU...
